Open-label, three period, randomized drug-drug interaction study of Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) and Atorvastatin in healthy subjects

Trial Profile

Open-label, three period, randomized drug-drug interaction study of Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) and Atorvastatin in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2016

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top